Lung Diseases Research
Mount Sinai is currently conducting a number of research studies and clinical trials to improve the diagnosis and treatment of a range of pulmonary diseases and conditions.
Lung Disease Research Areas
Investigators at the Division of Pulmonary, Critical Care and Sleep Medicine are studying the following areas in order to improve the detection and treatment of lung disease.
- Exploring biological indicators of aggressive early-stage lung cancer. This research seeks to understand the cellular changes that cause a slowly growing lung cancer to become aggressive. While more early-stage lung cancers are being detected through CT screenings, such imaging techniques cannot determine how fast cancers are growing. Using mouse models, our investigators have identified biological factors that drive tumor aggressiveness, paving the way for the development of new diagnostic markers and potential therapies that may help prevent or treat malignant tumors. New tests could be used to guide treatment decisions, including the extent of surgical removal of the cancer and the use of post-op therapies to prevent the cancer’s return.
- Integrating palliative and traditional care. Investigators are evaluating methods of combining palliative care approaches with the traditional management of critically ill cancer patients. Previous research has shown that outcomes of patients who are seriously ill with cancer are improved by the formal integration of palliative care principles. Such findings have helped transform the care provided to patients in the Intensive Care Unit.
- Studying immune-fighting cells in the lung. Investigators are conducting basic research into dendritic cells, which patrol the body for abnormalities and teach other immune cells to fight cancer and infection. These cells are well characterized in other tissues but not in the lung, so Mount Sinai researchers have developed sophisticated methods of identifying their location and mechanism. Our goal is to increase our understanding of the role of dendritic cells in regulating immune response, especially in patients with autoimmune diseases and immune deficiencies.
Lung Disease Clinical Trials
Mount Sinai’s Division of Pulmonary, Critical Care and Sleep Medicine is conducting clinical trials in the following three areas.
- Interstitial lung disease. Mount Sinai is one of a small number of centers participating in a trial to test the effectiveness of the drug Pirfenidone in the treatment of IPF (idiopathic pulmonary fibrosis).
- Chronic Obstructive Pulmonary Disease (COPD). Mount Sinai is participating in a few trials to examine the effectiveness of new brochodilator medications for managing symptoms of COPD. We also are involved in clinical research to improve the management of inpatients with COPD, with the goal of improving the transition from inpatient to outpatient care and reducing readmissions.
For more information on clinical trials:
5 East 98th Street, 8th Floor
New York NY 10029